Feature|Videos|July 16, 2025
The Ins and Outs of Value-Based Contracts: Timing, Evidence, and Risk Alignment
Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.
Advertisement
Episodes in this series
There is no shortcut to executing a value-based contract. In this episode, experts lay out what’s required to bring these agreements to life: evidence alignment, data compatibility, and mutual incentive. Payers want results, not just risk transference—and developers must understand and speak to payer business goals.
Key discussion topics include:
- Timeline and prerequisites for executing value-based contracts.
- Understanding what matters to payers vs. regulators.
- How to prototype contracting models for early feedback.
- The importance of strong head-to-head clinical data as the foundation.
Advertisement
Related to this article
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
3
The Unmet Needs That Will Define the Next Generation of GLP 1s: Q&A with Dr. Bo Liang
4
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
5